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Objective: To assess the incidence of lupus anticoagulant (LAC) in patients with peripheral vascular disease. 
Design" Prospective clinical study. 
Setting.. University Hospital. 
Materials: 20 patients with claudication (group 2), 20 patients with critical ischaemia (group 3) and 20 patients prior to 
elective abdominal ortic aneurysm surgery (group 4) were compared to 20 general surgical controls (group 1). 
Chief outcome measures: Venous blood samples for coagulation assay. 
Main results: Positive results for LAC by the Dilute Russell's viper venom time (DRVVT) with the platelet neutralisation 
procedure were present in 26 out of 60 vascular patients compared with none of the 20 general surgical controls. The three 
vascular groups showed a similar prevalence of LAC and this differed significantly from that in the control group 
(~ = 10.94, p = 0.0009). Of the 26 positive results only three were associated with an abnormal activated partial 
thromboplastin me (APTT), which has previously been used as a marker for the presence ofLAC activity. Fibrinogen 
levels were raised in seven of 20 patients in group 2 but were normal in the remaining vascular groups (p = 0.001). The 
mean factor VII level (124.1 units d1-1) in group 2 was higher than the mean of the remaining vascular patients (109.3 
units dl -~, p < 0.05). 
Conclusions: The high prevalence ofLAC in patients with peripheral vascular disease and the associated increased risk of 
early graft thrombosis may justify routine testing by DRVVT prior to reconstructive ascular surgery. Treatment ofthese 
patients with antiplatelet agents or formal anticoagulation perioperatively should be considered. 
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Introduction 
A hypercoagulable state exists when there is an 
imbalance in the coagulation - fibrinolytic system. 
Hypercoagulable states were initially associated with 
spontaneous venous thrombosis B but are becoming 
increasingly recognised in association with arterial 
thrombosis. 1"4"s The prevalence of hypercoagulable 
states is not known, with the majority of literature to 
date in the form of case reports or retrospective 
studies of patients recognised as suffering a hyper- 
coagulable state following an episode of thrombo- 
sis.a, 4, 6, 7 Two prospective studies have demonstrated 
a significant association between the presence of a 
hypercoagulable state and early infrainguinal graft 
thrombosis.~, s We have investigated the incidence of 
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abnormalities of the coagulation, procoagulant and 
naturally occurring anticoagulant pathways in 
patients with peripheral vascular disease. 
Patients, Materials and Methods 
Following approval by the local Research Ethics 
Committee, four groups of 20 patients were studied. 
The groups are described in Table 1. 
The following patients were excluded: those 
taking anticoagulants, antiplatelet drugs, drugs 
known to induce systemic lupus erythematosus (SLE), 
drugs known to induce lupus anticoagulant. Also 
those patients uffering a malignant process, diabetes 
mellitus or showing evidence of an acute inflamma- 
tory process were excluded as these disorders may 
produce false positive results. A full medical histor~ 
including smoking history was obtained. 
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Table 1. Patient groups studied (n = 20 for each group) 
Group 1 General surgical patients (preoperative) without a
history, or evidence, ofclinical peripheral vascular 
disease, with an ankle brachial index >__ 1.0, in the 
absence ofDiabetes Mellitus 
Group 2 Patients suffering intermittent claudication, with an 
ankle brachial index < 0.8 but > 0.4 
Group 3 Patients with critical limb ischaemia, with an ankle 
systolic pressure ofless than or equal to 50 mm Hg but 
without ulceration organgrene (44) 
Group 4 Patients awaiting elective abdominal ortic aneurysm 
repair 
General exclusion criteria 
Patients receiving anticoagulant or antiplatelet therapy. 
Drugs known to induce systemic lupus erythematosus (SLE), or 
lupus anticoagulant. 
Malignant disease, diabetes mellitus and acute inflammatory 
process. 
Venous blood samples were collected by ven- 
epuncture using a 19Ch needle without the applica- 
tion of a tourniquet whenever possible. The blood was 
collected into 3.8% trisodium citrate 10% by volume. 
Platelet poor plasma was prepared by centrifugation 
at 2000 × g for 15 rain at room temperature for factor 
VII or prothrombin time assays, and at 4°C for other 
coagulation assays. The preparation of all samples 
was completed within 1 h of collection. Where assays 
were performed in batches the platelet poor plasma 
was stored at-70°C. 
The following coagulation assays were 
performed: 
Activated Partial Thromboplastin Time (APTT)(nor- 
real range 35-51s). This was performed using a semi- 
automated technique, using reagents with low phos- 
pholipid content, using a 1:10 dilution in imidazole 
buffer to increase the diagnostic sensitivity for lupus 
anticoagulant (for further details refer to the manu- 
facturers product information: "DIAGEN" kaolin/ 
platelet substitute mixture, Diagnostic Reagents Lim- 
ited (Oxon, England, U.K.)). 
Kaolin Clotting Time (KCT) using the method devel- 
oped by Exner s (normal range 0.93-1.20). 
Thrombin Clotting time (TCT): the patients TCT 
should be within 3 s of a control plasma. 
One Stage Prothrombin Time (OSPT) 9 
The dilute Russell viper venom time (DRVVT) utilis- 
ing the platelet neutralisation procedure (PNP) was 
used to detect lupus anticoagulant activity following 
guidelines set out by the British Committee for 
Standardisation in Haematology. ~° Results were deter- 
mined to be abnormal if they exceeded two standard 
deviations from a mean, obtained from assessing the 
DRVVT on 50 samples of normal plasma (normal 
range 0.94 - 1.19). 
Factor VII was assayed using a one stage factor VII 
coagulant assay, based on the one stage prothrombin 
time test (OSPT). This is based on the premise that in 
a system devoid of Factor VII, but with all other 
factors for coagulation present in excess, the clotting 
time in the OSPT is dependent on the amount of 
Factor VII added to the factor VII deficient plasma. 
The choice of Factor VII deficient plasma is paramount 
as even a 1% residual factor VII level can lead to 
significant error. Reagents: Factor VII depleted plasma 
and normal control plasma level 1, Sigma Diagnostics 
(St. Louis, Mo, U.S.A.). Manchester Thromboplastin 
(Manchester Thrombosis Research Foundation, Man- 
chester, U.K.), calcium chloride Analar Volumetric 
solution, Merck Ltd. (Germany), 1:40 dilution to 
achieve 0.025 mol/1. Doubling dilution's of control 
plasma are made by the addition of imidazole buffer 
pH 7.3, to obtain 1:10 to 1:160, thus giving levels of 
Factor VII of 100% to 6.25%. The following are placed 
in a prewarmed KC10 cuvette: 50~tl Factor VII 
depleted plasma, 50~1 diluted control plasma, 50~1 
Manchester Thromboplastin. These are mixed and 
warmed to 37°C. Using the start pipette of the KC10, 
50~1 of prewarmed Calcium chloride 0.025 mol/1 is 
added and the coagulation time recorded. A standard 
dose response curve is plotted on 3 cycle log/log 
graph paper. The same procedure is performed on 
patient plasmas and the Factor VII level is 
calculated: 
Factor VII level in the sample = reading from graph 
× (plasma dilution factor/10). The normal range = 
50 -200%. 
Fibrinogen (factor II) levels were assayed using the 
method described by Clauss (Boehringer 
Mannheim). 1~ 
Free and total protein S was assayed by ELISA using 
DAKO rabbit anti-human protein S (A-384) as the 
captive antibody and DAKO perioxidase conjugated 
rabbit anti human protein S as the detection anti- 
body. 12 This method allows for simultaneous meas- 
urement of free and total protein S. 
Protein C, tissue plasminogen activator (tPA), plasmi- 
nogen activator inhibitor (PAI) were measured by 
chromogenic assay as per the manufacturers recom- 
mendations (Kabi Diagnostica, Sweden). 
Antithrombin III (AT III) levels were measured using a 
chromogenic assay as per the manufacturers instruc- 
tions (Baxter Dade, Switzerland). 
Anticardiolipin Antibodies (ACA), IgG and IgM, were 
assayed using a solid phase ELISA technique, results 
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Table 2. Coagulation assays and normal ranges 
Coagulation assay Normal ranges 
Activated partial thromboplastin me 
Kaolin clotting time 
Thrombin clotting time 
One stage prothrombin time 




Protein S (total) 
Protein S (free) 
Antithrombin III
Plasminogen 
Plasminogen activator inhibitor I 
Tissue type plasminogen activator 
Anticardiolipin antibodies IgM 
Anticardiolipin antibodies IgG 
Prolongation of _~ 8 seconds compared to control plasma 
Ratio 0.93 - 1.20 
Prolongation of ~ 2 seconds compared to control plasma 
Prolongation of _> 2 seconds compared to control plasma 











< 2.0 units 
< 2.0 units 
exceeding five standard deviations from the mean 
were deemed abnormal. 
Control Plasma Level 1 was obtained from Sigma 
Diagnostics (St. Louis, Mo, U.S.A.). The coagulation 
assays were carried out using a semi-automated 
technique on a KC Series (KC10) machine, AMELUNG 
(West Germany). Assays and normal values are 
summarised in Table 2. 
With the exception of anticardiolipin antibody, all 
assays were performed in the Department of Haema- 
tology coagulation laboratories. Anticardiolipin anti- 
body assays were performed in the department of 
Rheumatology Research Laboratories. The patients 
also underwent a physical examination and had a full 
blood count, plasma glucose estimation and a fasting 
lipid profile performed. 
Statistical analysis was performed using Stat 
View II TM (Abacus Concepts Incorporated) on an 
Apple Macintosh IIci (Apple Computers, Cupertino, 
California, U.S.A.). 
Results 
Eighty patients underwent the above assessment. All 
patients in the control group had normal coagulation 
assays. The mean (S.E.M.) age was 64 (3.44) for general 
surgical controls and 68 (1.61) for patients with 
peripheral vascular disease. There was no significant 
difference in age for the two groups using the two 
tailed unpaired t-test (t = 1.168, p = 0.246, NS and F = 
1.152, p -- 0.113, NS). For the purposes of this study it 
was not possible to match the patients by sex. There 
was no significant difference in smoking habits 
between the control and patient groups (9( 2 with 
continuity correction = 0.883, p = 0.3473). 
Lupus anticoagulant activity was present in 27 
patients with vascular disease. This differed sig- 
nificantly from the control group of patients (?(z with 
continuity correction -- 10.94, p < 0.0009). Nine 
patients with intermittent claudication, seven patients 
with critical ischaemia, and 11 patients with an 
abdominal aortic aneurysm were positive for LAC 
(Table 3). The difference was significant for each group 
compared to the control group (9( 2 with continuity 
correction -- 15.83, p = 0.001, 9( 2 with continuity correc- 
tion = 15.83, p = 0.0001, X 2 with continuity correction 
= 10.8, p < 0.001 respectively). 
Anticardiolipin antibodies were present at a level 
greater than 2 units in five patients, and were of the 
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Table 3. Lupus anticoagulant results by group 
Group 1 
General Surgical controls No positive results 
Group 2 
Intermittent Claudication 9/20 positive 
Group 3 
Critical Ischaemia 7/20 positive 
Group 4 
Abdominal Aortic Aneurysrn 11/20 positive 
IgM class. These were found in two patients in group 
2, one of which was positive for LAC, two patients in 
group 3, one of which was positive for LAC and one 
patient in group 4 that was also positive for LAC. 
The fibrinogen (factor II) level was normal for all 
patients in groups 2 and 4 but was significantly 
elevated in seven patients in group 3, (p=0.001 
unpaired t-test) (Fig. 1). Factor VII levels, for all 
groups, were within normal limits, but the mean 
factor VII level was significantly higher in group 3 
(p < 0.05 unpaired t-test). 
Antithrombin III was normal in all patients. A 
low protein C level was detected in one patient in 
group 3, this patient also tested positive for lupus 
anticoagulant. Total protein S and free protein S levels 
were normal in all patients. Plasminogen levels were 
low in only one patient from group 3. This patient was 
also positive for LAC and anticardiolipin antibodies. 
Other fibrinolytic proteins, plasminogen activator 
inhibitor, and tissue plasminogen activator were nor- 
mal. Routine coagulation screens were abnormal in 
only four cases, three APTT results were prolonged 
due to the presence of lupus anticoagulant activity 
and one OSPT was prolonged in a patient with 
abnormal liver function. The APTT was prolonged in 
only three cases giving a sensitivity of 12% and 
specificity of 94% for the detection of LAC activity if 
the APTT was the only screening method used. 
Discuss ion  
Hypercoagulable states are clinical syndromes consist- 
ing of an increased or unusual predisposition to 
thrombosis. Their importance is becoming increas- 
ingly recognised and they are especially relevant o 
vascular surgeons and radiologists as post-inter- 
ventional thrombosis is increased. 13 The incidence of 
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majority of the information relating to these states in 
surgical patients has been collected retrospectively. 
The most frequently encountered abnormalities of 
coagulation and fibrinolysis are antithrombin III defi- 
ciency, protein C, protein S deficiencies and the 
presence of antiphospholipid antibodies. 13
We did not discover any abnormalities of antith- 
rombin III or the fibrinolytic system in the study 
which may be explained by their relatively low 
prevalence. Antithrombin III deficiency has a preva- 
lence of between 1:2000 to 1:5000 in the general 
population. 13Protein C deficiency discovered in one 
case in combination with LAC is of interest as LAC 
has been associated with reduced protein C activa- 
tion. ~4-~6 Patients with critical ischaemia were found 
to have an elevated fibrinogen level and this has been 
associated with an increased risk of coronary throm- 
bosisY The elevated fibrinogen level may reflect he 
general increase of the acute phase proteins, which 
include fibrinogen, that is seen in response to ischae- 
mia. The higher mean factor VII levels in patients with 
critical ischaemia can not be explained by this mecha- 
nism and it should be noted that elevation of factor VII 
is an independent risk factor for ischaemic heart 
disease, but has not been demonstrated to be a risk 
factor for peripheral vascular disease. 18'19 Further 
studies are required to assess the significance of this 
finding. The combination of elevated factor VII and 
fibrinogen in critical ischaemia may partly explain the 
increased occurrence of spontaneous thrombotic epi- 
sodes in these high risk patients. 
Our study has shown a high prevalence of lupus 
anticoagulant in patients with vascular disease, that 
has not been reported previously. Lupus anticoagulant 
is an antiphospholipid antibody; directed against 
negatively charged phospholipid. It is most often of 
the IgG class, but LAC activity has also been demon- 
strated in IgM and IgA fractions. 2°' 21 Lupus anticoag- 
ulant was first noted in patients with systemic lupus 
erythematosus where it was observed that there was 
an in vitro prolongation of phospholipid ependant 
coagulation assays, for example the partial thrombo- 
plastin time. 22 Following multiple reports of thrombo- 
tic events associated with the presence of the LAC it 
was apparent that the term 'lupus anticoagulant' was 
a misnomer. 23-26 Antiphospholipid antibodies are 
increasingly being recognised in the absence of con- 
nective tissue disorders in association with thrombo- 
sis. 27'28 The LAC is associated with a significantly 
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thrombosis. A retrospective study by Ahn revealed a
43% incidence of thrombosis following vascular proce- 
dures in seven patients positive for LAC and this was 
significantly higher than patients that had undergone 
non-vascular procedures (p < 0.025). 2 Further reports 
of an increased rate of thrombosis in patients with 
LAC have followed. Eldrup-Jorgansen reported nine 
of 57 patients (8%) undergoing lower extremity 
arterial reconstructions that tested positive for LAC. 
The postoperative thrombosis rate in these patients 
was 20%, despite perioperative anticoagulation. 4 One- 
hundred-and-eighty-seven patients with vascular dis- 
ease were screened for the presence of a hyper- 
coagulable state and the incidence of LAC was 3.4%. 5 
The low incidence of LAC reported may be explained 
by the variety of tests and criteria that have been used 
to identify LAC activity. Eldrup-Jorgansen relied on 
prolongation of the PTT > 5 seconds with correction 
with the addition of phospholipid; the study by 
Donaldson used the Russell's viper venom time but 
without phospholipid neutralisation procedure which 
leads to the possibility of missing patients that are 
positive for LAC using the PTT. Also patients may be 
classified as positive for LAC when there is a 
deficiency of factors V and X if the platelet neutral- 
isation procedure is not utilised. 29 If we had used the 
APTT as a screening test for LAC we would have 
detected only three out of 25 cases that were positive 
giving a rate of 12%. The controversy regarding the 
appropriate test for LAC has been reduced following 
the recommendations of national and international 
working parties. 1°'3° We have followed these recom- 
mendations and our results are likely to reflect he true 
prevalence of LAC in vascular patients. 
Mechanisms proposed to account for the pathoge- 
nesis of thrombosis in patients with LAC include a 
reduction in production by the vascular endothelium 
of the prostaglandin prostacyclin, the most potent 
natural inhibitor of platelet aggregation and vasodila- 
tor. 31 This may lead to platelet thrombus forma- 
tion.24, 32, 33 However this has not been con- 
15 34-36 firmed. ' Inhibition of the natural anticoagulants 
protein C and protein S have been demon- 
strated.~6, 37,38 These proteins inactivate factor V and 
factor VIII of the coagulation cascade, and also 
promote fibrinolysis by inactivating tissue plasmino- 
39 40 gen activator inhibitor. ' Increased platelet aggrega- 
tion in the presence of antiphospholipid antibodies 
has been shown in a perfusion system in vitro. 41 It is 
unlikely that a single mechanism can account for the 
thrombotic tendency seen in patients with anti- 
phospholipid antibodies and that a combination of 
several mechanisms lead to a thrombotic event. 
It has been suggested that LAC may be an 
epiphenomenon reflecting endothelial/vessel wall 
damage, which exposes phospholipids not usually 
expressed by the intact endothelium leading to the 
formation of these autoantibodies. 42 Thrombosis in 
patients with phospholipid antibodies often presents 
in the young, with little or no angiographic evidence 
of atherosclerosis. 43 The significance of the finding of a 
very high prevalence of the LAC in patients with 
peripheral vascular disease remains to be answered 
and there is a need for long-term prospective follow- 
up studies. 
Lupus anticoagulant is highly prevalent in 
patients with peripheral vascular disease. Prospective 
follow up studies are required to assess the predictive 
value of LAC for thrombosis. If shown to be a useful 
prognostic indicator for thrombosis, screening for 
LAC should be adopted. 
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